Your browser doesn't support javascript.
loading
Effects of a Long-Acting Diquafosol Ophthalmic Solution on the Ocular Surface, Tolerability, and Usability in Dry Eye Disease.
Kaido, Minako; Arita, Reiko.
Afiliação
  • Kaido M; Wada Eye Clinic, Houjyo 2578-27, Tateyama-shi, Chiba, 294-0045, Japan. tomoulton777@ff.em-net.ne.jp.
  • Arita R; Itoh Clinic, Saitama, 337-0042, Japan.
Adv Ther ; 41(6): 2477-2485, 2024 Jun.
Article em En | MEDLINE | ID: mdl-38709396
ABSTRACT

INTRODUCTION:

This study aimed to investigate the tolerability of high-viscosity diquafosol tetrasodium (DQS) ophthalmic solution (DIQUAS LX; DQSLX) and examine its usability and effect on clinical findings in patients with dry eye disease (DED).

METHODS:

This interventional retrospective study included 66 eyes of 66 patients with DED who switched from conventional DQS to DQSLX ophthalmic solution. Tear function assessments (tear film breakup time [BUT], keratoconjunctival vital staining [VS] score), evaluations of DED symptom relief, and a four-item usability questionnaire ("comfort upon instillation," "irritation upon instillation," "eye mucus discharge," "convenience of instillation frequency") assessed using a visual analog scale from 0 (worst) to 10 (best) were administered 4 weeks after switching to DQSLX. Factors associated with drug tolerability were assessed using multiple regression analysis.

RESULTS:

The symptoms improved by 64.2% after switching to DQSLX. The BUT value, VS score, and the questionnaire items "comfort upon instillation" and "convenience of instillation frequency" were significantly improved after switching to DQSLX. DQSLX tolerability was reported as acceptable in 56 (84.8%) and unacceptable in 10 (15.2%) patients. Overall, DQSLX tolerability was significantly associated with "comfort upon instillation" and "convenience of instillation frequency" and tended to be associated with a VS score ≥ 1. DQSLX tolerability depended on symptom and VS score improvements and absence of excessive "eye mucus discharge" in patients with a VS score ≥ 1 (39 patients), but on "comfort upon instillation" and absence of excessive "eye mucus discharge" in patients with a VS score = 0 (27 patients).

CONCLUSION:

The high-viscosity DQSLX ophthalmic solution was generally considered acceptable in the study population. However, drug tolerability seemingly differed between patients with DED with and without epithelial damage. The former were affected by improvements in symptoms and clinical findings, whereas the latter were affected by comfort upon instillation. TRIAL REGISTRATION University Hospital Medical Information Network identifier, UMIN000051390.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Soluções Oftálmicas / Polifosfatos / Nucleotídeos de Uracila / Síndromes do Olho Seco Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Adv Ther Assunto da revista: TERAPEUTICA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Japão

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Soluções Oftálmicas / Polifosfatos / Nucleotídeos de Uracila / Síndromes do Olho Seco Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Adv Ther Assunto da revista: TERAPEUTICA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Japão